Newbridge Financial Services Group Inc. Invests $72,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 2,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $72,000.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in shares of Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 398 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after buying an additional 352 shares during the period. KBC Group NV lifted its position in Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after buying an additional 929 shares in the last quarter. Kennebec Savings Bank purchased a new stake in Supernus Pharmaceuticals during the third quarter worth approximately $103,000. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth $211,000.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $37.93 on Tuesday. The company’s fifty day moving average price is $37.38 and its two-hundred day moving average price is $34.90. The firm has a market capitalization of $2.09 billion, a P/E ratio of 35.45 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28.

Analyst Upgrades and Downgrades

SUPN has been the subject of a number of research reports. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cantor Fitzgerald began coverage on Supernus Pharmaceuticals in a research report on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price for the company. Finally, Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. The trade was a 6.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.